The performance ceiling for non-invasive Brain-Computer Interfaces (BCIs) is rising dramatically, not from better sensors, but from advanced AI. New models can extract high-fidelity signals from noisy data collected outside the skull, potentially making surgical implants like Neuralink unnecessary for sophisticated use cases.

Challenging Neuralink's implant-based BCI, Merge Labs is creating a new paradigm using molecules, proteins, and ultrasound. This less invasive approach aims for higher bandwidth by interfacing with millions of neurons, fundamentally rethinking how to connect brains to machines.

Dr. Casey Halpern argues that creating precise, non-invasive treatments like focused ultrasound or TMS for psychiatric disorders depends on invasive research. By placing electrodes deep in the brain, researchers can map the exact circuits responsible for symptoms. This invasive data is essential to define accurate targets for future non-invasive technologies.

While current brain-computer interfaces (BCIs) are for medical patients, the timeline for healthy individuals to augment their brains is rapidly approaching. A child who is five years old today might see the first healthy human augmentations before they graduate high school, signaling a near-term, transformative shift for society.

While companies like Neuralink popularize assistive BCIs for controlling external devices, a different segment is focused on therapeutic applications. Companies like InBrain aim not to control computers but to use high-resolution interfaces to directly heal or modulate neural circuits for treating diseases.

A "frontier interface" is one where the interaction model is completely unknown. Historically, from light pens to cursors to multi-touch, the physical input mechanism has dictated the entire scope of what a computer can do. Brain-computer interfaces represent the next fundamental shift, moving beyond physical manipulation.

New artificial neurons operate at the same low voltage as human ones (~0.1 volts). This breakthrough eliminates the need for external power sources for prosthetics and brain interfaces, paving the way for seamless, self-powered integration of technology with the human body.

Paradromics measures its technological advancement by the number of neurons it can record from, directly impacting the BCI's data rate. This "neurons per device" metric serves as an industry benchmark, similar to how transistor density drove progress in semiconductors.

Graphene's combination of extreme flexibility, superior conductivity, and biocompatibility directly addresses the failures of rigid metal electrodes. This allows for high-resolution BCIs that conform to the brain's surface, enabling more precise and stable neural stimulation and recording for long-term treatment.